EDP at Medica 2010 Pictured Below
EDP Biotech Corporation is a privately held medical device company focused on the development and commercialization of blood based immunodiagnostic assays incorporating EDP100 and EDP200 biomarkers. EDP100 and EDP200 Biomarkers are fully characterized, incorporated into Enzyme-Linked Immunosorbent Assays (ELISA) and undergoing various IRB Sanctioned Trials to confirm "clinical utility" for specfic Oncology Disease States. EDP100 and EDP200 Biomarker IP (Intellectual Property) is Patent Pending.* These tests are not available or approved for public diagnostic screening at this time.
EDP's biomarker identifies specific proteins at pre-symptomatic stages known to be elevated within the blood of individuals harboring certain cancers.
*EDP Biotech Corporation's IP is represented and managed by Merchant & Gould